1,041 material Form 8-K filings that 824 companies we cover made with the SEC in November 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Viasat reported fiscal second-quarter 2026 results, with revenue of $1.1 billion up 2% from a year earlier and a net loss of $61 million, compared with $138 million a year earlier. The company reiterated most of its fiscal 2026 outlook, including low single-digit revenue growth and flattish Adjusted EBITDA, so shareholders see improved headline results with guidance held steady rather than changed.
Q2 FY2026 revenue was $1.1 billion, up 2% year over year, led by 3% growth in Defense and Advanced Technologies.
Net loss attributable to Viasat was $61 million, versus $138 million in Q2 FY2025.
Adjusted EBITDA was $385 million, up 3% year over year; free cash flow was $69 million.
Fiscal 2026 guidance was kept for low single-digit revenue growth and flattish Adjusted EBITDA; net debt was $5.5 billion at quarter end.
Franklin Resources reported preliminary fourth-quarter results for the period ended September 30, 2025, with net income attributable to the company of $117.6 million, or $0.21 per diluted share, compared with a net loss of $84.7 million a year earlier. Operating revenues rose 6% year over year, while operating income fell from the prior quarter after a $202.2 million impairment of intangible assets, and the company reported $11.9 billion of long-term net outflows. For shareholders, the quarter shows a return to profit, while fiscal year adjusted diluted earnings per share declined to $2.22 from $2.39.
Q4 operating revenues were $2,343.7 million, up 6% from $2,211.2 million a year earlier and 14% from $2,064.0 million in the prior quarter.
Q4 net income attributable to Franklin Resources was $117.6 million, or $0.21 per diluted share, versus a net loss of $84.7 million, or $0.19 per share, in Q4 fiscal 2024.
Q4 operating income was $85.4 million, down 45% from $154.1 million in the prior quarter, after a $202.2 million impairment of intangible assets.
Q4 adjusted diluted earnings per share were $0.67, up from $0.49 in the prior quarter and $0.59 a year earlier; fiscal year adjusted net income was $1,195.8 million, down 6%.
ANI Pharmaceuticals reported third-quarter 2025 net revenues of $227.8 million, up 53.6% from a year earlier, and GAAP net income attributable to common shareholders of $26.3 million, or $1.13 per diluted share, compared with a loss of $1.27 per share in the prior-year quarter. The company raised its full-year 2025 total net revenue guidance to $854 million to $873 million and its adjusted non-GAAP EBITDA guidance to $221 million to $228 million, which points to higher expected results for shareholders.
Q3 2025 net revenues were $227.8 million, up 53.6% from $148.3 million in Q3 2024.
Cortrophin Gel net revenues were $101.9 million, up 93.8% year over year.
GAAP diluted EPS was $1.13 versus a loss of $1.27 a year earlier; adjusted non-GAAP diluted EPS was $2.04.
2025 total net revenue guidance was raised to $854 million to $873 million, from $818 million to $843 million; ILUVIEN net revenue was $16.6 million in the quarter, which the company said was pressured by reduced Medicare access.
KKR reported third quarter 2025 results on November 7, 2025. GAAP net income attributable to KKR common stockholders was $859.9 million, or $0.90 per diluted share, compared with $600.6 million, or $0.64, a year earlier, while total revenues rose to $5.53 billion from $4.79 billion. Fee Related Earnings reached a record $1.0 billion, and new capital raised was $43 billion.
GAAP net income to KKR common stockholders of $859.9 million, or $0.90 diluted per share, versus $600.6 million, or $0.64, in 3Q'24
Total revenues of $5.53 billion, up from $4.79 billion a year earlier
Fee Related Earnings of $1.0 billion ($1.15 per adjusted share), a record for KKR and up 3% year over year
Regular dividend of $0.185 per share declared for the quarter; assets under management of $723 billion, up 16% year over year
Atmus Filtration Technologies reported third-quarter 2025 net sales of $448 million, up 10.9% from a year earlier, and diluted earnings per share of $0.66 versus $0.52. The company raised its full-year 2025 guidance and said it completed its operational separation from former parent Cummins Inc. For shareholders, the higher profit and raised outlook point to improved results, and the company also repurchased $30 million of its stock during the quarter.
Net sales of $448 million versus $404 million in the third quarter of 2024, an increase of 10.9%
GAAP net income of $55 million; diluted EPS of $0.66 versus $0.52; adjusted EPS of $0.69 versus $0.61
2025 guidance raised: revenue of $1,720 million to $1,745 million and adjusted EPS of $2.50 to $2.65
Repurchased $30 million of common stock; $69 million remained under the $150 million authorization as of September 30, 2025; quarterly dividend of $0.055 per share, up 10%
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.